Disc Medicine (IRON) stock price is $79.48, up 0.70% on the day, as of Oct 20, 2026. It has a market cap of $3.08Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap3.08 Bn
P/E-12.52
Div. Yield0.00
Total Debt (Qtr)59.34 Mn
Add ratio to table…
About
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery development and commercialization of novel treatments for patients with serious hematologic diseases. The company concentrates on modulating two fundamental pathways that govern red blood cell formation and function heme biosynthesis and iron homeostasis. Its pipeline includes product candidates that target the heme biosynthesis pathway to reduce toxic porphyrin accumulation and…
Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery development and commercialization of novel treatments for patients with serious hematologic diseases. The company concentrates on modulating two fundamental pathways that govern red blood cell formation and function heme biosynthesis and iron homeostasis. Its pipeline includes product candidates that target the heme biosynthesis pathway to reduce toxic porphyrin accumulation and product candidates that adjust hepcidin activity to either increase or decrease serum iron levels. These approaches aim to address conditions such as erythropoietic protoporphyria X linked protoporphyria anemia of myelofibrosis anemia of inflammatory bowel disease polycythemia vera sickle cell disease and other hematologic disorders.
Disc Medicine, Inc. has not yet commercialized any therapeutic product and therefore does not generate revenue from product sales. Its current financial resources are derived from licensing agreements milestone payments and equity financing activities. The company has entered into exclusive worldwide licenses for bitopertin DISC 0974 DISC 0998 and DISC 3405 which may yield future royalty payments upon successful approval and sale. Milestone payments received from partners under these agreements also contribute to cash inflow. Until a product receives regulatory approval and reaches market the primary focus remains on research and development rather than revenue generation.
The company operates in the highly competitive biopharmaceutical sector that focuses on rare hematologic diseases. Its main competitors include larger pharmaceutical firms such as Agios Pharmaceuticals Akebia Therapeutics Amgen Bristol Myers Squibb GlaxoSmithKline Incyte Corporation Merck and Company Otsuka Pharmaceutical and Vifor Pharma among others. For its heme biosynthesis program bitopertin the company faces competition from approved melanocortin 1 receptor agonists such as afamelanotide marketed as Scenesse and oral agents like dersimelagon. These existing therapies increase melanin production to improve sunlight tolerance but do not reduce the toxic metabolite protoporphyrin IX. Bitopertin differentiates itself by directly inhibiting glycine transporter 1 to lower protoporphyrin IX levels addressing the underlying disease mechanism. In the iron homeostasis arena DISC 0974 and DISC 3405 compete with erythropoiesis stimulating agents corticosteroids androgenic hormones and hepcidin modulating agents such as momelotinib and rusfertide. The company believes its competitive advantage lies in targeting genetically validated pathways that have demonstrated activity in human studies and in holding exclusive worldwide licenses for its product candidates. Its approach of modulating fundamental red blood cell biology aims to provide disease modifying therapy with a clear mechanistic rationale. These factors may help Disc Medicine, Inc. stand out in a crowded field of hematologic therapeutics.
Disc Medicine, Inc. intends to serve patients suffering from a range of hematologic disorders that stem from dysregulation of heme biosynthesis or iron homeostasis. The target patient populations include individuals with erythropoietic protoporphyria X linked protoporphyria anemia of myelofibrosis anemia of inflammatory bowel disease polycythemia vera sickle cell disease and other related conditions. Healthcare providers such as hematologists hepatologists gastroenterologists and transfusion centers are expected to administer the therapies once they become available. The company also engages with patient advocacy groups and clinical trial sites to support development and future commercialization efforts. While specific customer names are not disclosed in the filing the overall market consists of thousands of patients in the United States and abroad who suffer from the rare diseases mentioned.
Sector:HealthcareSector rationaleDisc Medicine is a clinical-stage biopharmaceutical company developing novel treatments for hematologic diseases, such as sickle cell disease and anemia of myelofibrosis. Its business model is centered on the discovery, development, and future commercialization of medical therapeutics, which falls squarely within the Biotechnology and Pharmaceuticals industries of the Healthcare sector.Industry:BiotechnologyBiotechnologyPrimaryDisc Medicine is a clinical-stage biopharmaceutical company developing therapies derived from biological science to treat hematologic diseases. Its revenue model currently relies on licensing agreements and milestone payments for candidates like bitopertin, DISC 0974, and DISC 0998.Classified using BQ-MICSCIK: 0001816736
Bull & bear
Investment Thesis
▲ Bull case
Disc Medicine (IRON) possesses a compelling long-term value proposition rooted in the significant unmet medical need for erythropoietic protoporphyria (EPP) patients, a rare and debilitating condition with no approved disease-modifying therapies currently available. Bitopertin, the company's lead asset, targets the underlying pathophysiology of EPP by inhibiting glycine uptake in the liver, thereby reducing the overproduction of protoporphyrin that causes extreme photosensitivity. The ongoing late-stage trial, expected to deliver results in Q4 FY26, is designed with robust clinical endpoints that directly measure patient-relevant outcomes such as pain-free time in sunlight and quality of life improvements, which are more likely to resonate with regulators and payers than surrogate biomarkers alone. Management has consistently emphasized that the FDA's concerns regarding the accelerated approval pathway are "readily addressable" through the completion of this pivotal study, suggesting confidence in the drug's ability to demonstrate clear clinical benefit. Furthermore, the shift to a traditional approval pathway, while extending the timeline to mid-2027, ultimately positions bitopertin for broader market access, stronger reimbursement prospects, and greater physician adoption due to the higher evidentiary standard required for full approval. The recent share price rebound following the news of pursuing traditional approval indicates investor recognition that the setback is procedural rather than fundamental to the drug's efficacy or safety profile. With no direct competitors in the disease-modifying space for EPP, Disc Medicine (IRON) stands to capture near-total market share in a niche but willing-to-pay patient population upon successful launch, creating a durable revenue stream with significant pricing power.
Disc Medicine (IRON) possesses a compelling long-term value proposition rooted in the significant unmet medical need for erythropoietic protoporphyria (EPP) patients, a rare and debilitating condition with no approved disease-modifying therapies currently available. Bitopertin, the company's lead asset, targets the underlying pathophysiology of EPP by inhibiting glycine uptake in the liver, thereby reducing the overproduction of protoporphyrin that causes extreme photosensitivity. The ongoing late-stage trial, expected to deliver results in Q4 FY26, is designed with robust clinical endpoints that directly measure patient-relevant outcomes such as pain-free time in sunlight and quality of life improvements, which are more likely to resonate with regulators and payers than surrogate biomarkers alone. Management has consistently emphasized that the FDA's concerns regarding the accelerated approval pathway are "readily addressable" through the completion of this pivotal study, suggesting confidence in the drug's ability to demonstrate clear clinical benefit. Furthermore, the shift to a traditional approval pathway, while extending the timeline to mid-2027, ultimately positions bitopertin for broader market access, stronger reimbursement prospects, and greater physician adoption due to the higher evidentiary standard required for full approval. The recent share price rebound following the news of pursuing traditional approval indicates investor recognition that the setback is procedural rather than fundamental to the drug's efficacy or safety profile. With no direct competitors in the disease-modifying space for EPP, Disc Medicine (IRON) stands to capture near-total market share in a niche but willing-to-pay patient population upon successful launch, creating a durable revenue stream with significant pricing power.
Disc Medicine (IRON) faces substantial near-term and mid-term risks that the market may be underestimating following the FDA's rejection of bitopertin under the accelerated approval pathway, particularly concerning the durability of the drug's clinical data and the evolving regulatory landscape for rare disease therapies. The agency's explicit concerns about whether pain-free time in sunlight—a secondary endpoint in prior trials—constitutes a statistically valid measure of efficacy raise serious questions about the robustness of the existing data package, especially given that the FDA also questioned whether biomarker reductions in protoporphyrin levels truly correlate with meaningful clinical benefit. This regulatory skepticism is compounded by cited concerns over the drug's potential for abuse, which, while not fully detailed in public filings, introduces an unprecedented safety and reputational risk for a rare disease therapy that could trigger additional scrutiny, risk evaluation and mitigation strategies (REMS), or even deter physician prescribing. Management's assertion that the issues are "readily addressable" relies heavily on the success of the ongoing late-stage trial, yet there is no guarantee that modifying the trial design or extending follow-up will resolve the FDA's fundamental doubts about endpoint validity or abuse potential. Furthermore, the company's admission that modifying the late-stage trial "is not on the menu right now" limits its ability to adapt to regulatory feedback in real time, increasing the risk of another complete response letter. The projected mid-2027 timeline for a potential traditional approval decision implies a prolonged period of cash burn without near-term revenue, heightening financing risk and potentially necessitating dilutive equity offerings or debt financing at unfavorable terms. Finally, the broader industry trend toward stricter evidentiary standards for accelerated approvals, as acknowledged by both analysts and the CEO, suggests that Disc Medicine (IRON) may be operating in a regulatory environment where even positive late-stage results could face unexpected hurdles, making the path to commercialization significantly more uncertain and costly than currently anticipated by investors.
Disc Medicine (IRON) faces substantial near-term and mid-term risks that the market may be underestimating following the FDA's rejection of bitopertin under the accelerated approval pathway, particularly concerning the durability of the drug's clinical data and the evolving regulatory landscape for rare disease therapies. The agency's explicit concerns about whether pain-free time in sunlight—a secondary endpoint in prior trials—constitutes a statistically valid measure of efficacy raise serious questions about the robustness of the existing data package, especially given that the FDA also questioned whether biomarker reductions in protoporphyrin levels truly correlate with meaningful clinical benefit. This regulatory skepticism is compounded by cited concerns over the drug's potential for abuse, which, while not fully detailed in public filings, introduces an unprecedented safety and reputational risk for a rare disease therapy that could trigger additional scrutiny, risk evaluation and mitigation strategies (REMS), or even deter physician prescribing. Management's assertion that the issues are "readily addressable" relies heavily on the success of the ongoing late-stage trial, yet there is no guarantee that modifying the trial design or extending follow-up will resolve the FDA's fundamental doubts about endpoint validity or abuse potential. Furthermore, the company's admission that modifying the late-stage trial "is not on the menu right now" limits its ability to adapt to regulatory feedback in real time, increasing the risk of another complete response letter. The projected mid-2027 timeline for a potential traditional approval decision implies a prolonged period of cash burn without near-term revenue, heightening financing risk and potentially necessitating dilutive equity offerings or debt financing at unfavorable terms. Finally, the broader industry trend toward stricter evidentiary standards for accelerated approvals, as acknowledged by both analysts and the CEO, suggests that Disc Medicine (IRON) may be operating in a regulatory environment where even positive late-stage results could face unexpected hurdles, making the path to commercialization significantly more uncertain and costly than currently anticipated by investors.